PET在常见非霍奇金淋巴瘤一线治疗中的作用
本综述聚焦18F-FDG PET在弥漫大B细胞淋巴瘤、滤泡性淋巴瘤和外周T细胞淋巴瘤评估中的应用。PET较CT可导致分期迁移,对早期弥漫大B细胞淋巴瘤和滤泡性淋巴瘤患者预后改善有贡献。中期PET可评估化疗敏感性,但不足以指导治疗调整;滤泡性淋巴瘤诱导化疗后PET可预测高肿瘤负荷患者预后。
要点
- PET较CT可导致分期迁移,对弥漫大B细胞淋巴瘤和滤泡性淋巴瘤的分期和预后有重要价值。
- 中期PET可评估化疗敏感性,但不足以预测治疗成功以指导治疗调整。
- 滤泡性淋巴瘤诱导化疗后PET可预测高肿瘤负荷患者预后,正作为反应 adapted 治疗平台评估。
核心结论
- PET在弥漫大B细胞淋巴瘤、滤泡性淋巴瘤和外周T细胞淋巴瘤的一线评估中具有重要作用,但中期PET不足以指导治疗调整。
研究设计与样本
- 本综述聚焦18F-FDG PET在弥漫大B细胞淋巴瘤、滤泡性淋巴瘤和外周T细胞淋巴瘤评估中的应用。
主要发现
- PET较CT可导致分期迁移,对早期弥漫大B细胞淋巴瘤和滤泡性淋巴瘤患者预后改善有贡献。
- 中期PET可评估弥漫大B细胞淋巴瘤和外周T细胞淋巴瘤的化疗敏感性,但不足以预测治疗成功以指导治疗调整。
- 滤泡性淋巴瘤诱导化疗后PET可预测高肿瘤负荷患者预后,正作为反应 adapted 治疗平台评估。
临床怎么用
- PET可用于弥漫大B细胞淋巴瘤、滤泡性淋巴瘤和外周T细胞淋巴瘤的分期和预后评估。
- 中期PET可用于评估化疗敏感性,但不应据此调整治疗。
- 滤泡性淋巴瘤诱导化疗后PET可用于预测高肿瘤负荷患者预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This Review focuses on the use of 18F-fluorodeoxyglucose (18F-FDG) PET in the assessment of diffuse large B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma. PET is important for staging and prognostication with stage migration compared with CT. Better outcomes for patients with early stage diffuse large B-cell lymphoma and follicular lymphoma suggests better delineation of disease has translated to improved outcomes in such patients beyond simple stage migration. The aim of treatment of diffuse large B-cell lymphoma and peripheral T-cell lymphoma is potential cure, during which PET is mainly used to assess remission. Interim PET can assess chemosensitivity in these lymphomas, but it does not predict treatment success sufficiently well to enable treatment modification, particularly in the absence of more effective therapies for patients who remain PET-positive on interim scanning. In follicular lymphoma, traditionally viewed as an incurable lymphoma, the aim of treatment is to control disease for several years, while maintaining quality of life. PET can predict prognosis for patients with follicular lymphoma with high tumour burden at the end of induction chemotherapy, and it is being evaluated as a platform for response-adapted treatment of follicular lymphoma.
引用
- Barrington SF, Trotman J. The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma. Lancet Haematol. 2020. PMID: 33357487. doi:10.1016/S2352-3026(20)30365-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。